A Phase 1, Open-Label, Multiple Ascending Dose Study to Investigate the Safety and Tolerability of Intravitreal Injections of OSA-2-100 in Subjects with Dry Age-Related Macular Degeneration (AMD)
Research Grant
Awarded By
Osanni Bio, Inc.
Start Date
April 2, 2024
End Date
January 7, 2026
Awarded By
Osanni Bio, Inc.
Start Date
April 2, 2024
End Date
January 7, 2026